Marian S. Wettstein

Great podium by @wettsteinms using @ICESOntario administrative data to suggest retrograde tumor cell seeding in urothelial CA. Decompression of upper tract ideally with nephrostomy (over stent) in patients with bladder CA. @GSK_UofT @UofT #CUA24

Caveat Emptor 🎯Read our Word of Wisdom in @EUplatinum about Stockholm3 in light of exciting times for PCa screening with TRANSFORM starting and ProScreen suggesting benefits of novel markers with @wettsteinms @MaartenvSmeden sciencedirect.com/science/articl…

@BJUIjournal Thank you @BJUIjournal for this honour! @GSK_UofT @ICESOntario @enenbee

Congratulations to the 2023 BJUI Americas Prize winner at #aua23, Marian Wettstein The winning paper is bjui-journals.onlinelibrary.wiley.com/doi/10.1111/BJ…

Congratulation to Marian Wettstein for winning the BJUI best paper @wettsteinms #AUA23

@UofTUrology @UofTSurgery @UroOncMD @UroOnc @UHN_Surgery 🥳🥳🥳

Congratulations to Dr Tony Finelli, our new Chair of Urology @UofTSurgery @UroOncMD @UroOnc @UHN_Surgery

✨our paper is now published: 💥MiR-371 immediately post orchiectomy not predictive for recurrences but detects recurrences reliably and earlier than standard follow-up investigations @Silke_Gillessen @wettsteinms @nico_grossmann rdcu.be/cDfy2

Cure, staging benefit, or both? Read our causal mediation analysis investigating the benefit of a more extended PLND among patients undergoing RP for localized PC. #prostatecancer @GSK_UofT link.growkudos.com/1fw272mtf5s onlinelibrary.wiley.com/doi/10.1002/pr…

Do ↗️ surgical case volumes translate into improved survival in T1 #bladdercancer and do we need centralization of care? The results of our study awarded with the CUA Prize Essay 2020 can be found in the current CUAJ issue! doi.org/10.5489/cuaj.6… @ICESOntario @CanUrolAssoc

Things that *can* change the big issues in medical science - higher investments in data collection and management - study methods (pre-)registration - open access of data, code and publication - mandatory reporting guidelines Boring huh?

Things that are *not* going to change the big issues in medical science - banning p-values, using confidence intervals to claim “effect” - banning odds ratio’s, using risk ratio’s for “effect size” - banning multivariable regression, using propensity scores for “confounding”

Non standardized reporting and flawed analyses of next-generation ADT adverse events. @Silke_Gillessen @apccc19 To be addressed in PCWG 4 and #APCCC21 ? europeanurology.com/article/S0302-…

NEW Research—Cumulative exposure to higher intensities of #mechanicalventilation was harmful, even for short durations Prospective cohort study from Eddy Fan & colleagues on time-varying intensity of mechanical ventilation and mortality bit.ly/3jMgXvR

Management of active surveillance-eligible #ProstateCancer during the pretransplantation workup of patients with #Kidney failure: a simulation study. #BeyondTheAbstract with @UweBieri and @wettsteinms. #ReadNow on UroToday > bit.ly/3e9aFTK @UZH_en @UofT

Is it necessary to wait for kidney transplantation in kidney failure patients with active surveillance-eligible prostate cancer? Check out our recent publication/podcast in @CJASN! Many thanks to @aakashshingada for such a great visual abstract!

Hence, the clinical significance may be limited. The FDA’s 9:4 vote in favor of pembro was probably mostly driven by the unmet clinical need and the fact that pembro outperformed prior less successful NTs such as valrubicin by far.

How to interpret our results in the light of the recent FDA approval of Pembro? Although the KEYNOTE‐057 investigators used a slightly different outcome measure, they did not meet our proposed efficacy thresholds.

Fresh from the press📰: Our decision analysis regarding the required efficacy for novel therapies in BCG-unresponsive bladder cancer. Do current recommendations really reflect clinically meaningful outcomes? May I take you on a walk-through? onlinelibrary.wiley.com/doi/full/10.10…